Abstract

When depression has not improved enough after treatment, guidelines first review the diagnosis and how earlier treatment went before the next step is chosen. The next options include switching medicines, adding a second medicine such as lithium or an antipsychotic, ketamine or esketamine, electroconvulsive therapy and repetitive transcranial magnetic stimulation. Adding a medicine, ketamine or esketamine, ECT and rTMS have each shown benefits in studies, while switching has not been shown to work better than staying on the same antidepressant; several options carry side effects, such as dissociation with ketamine and memory effects with ECT that are usually short-lived. Several questions remain uncertain, including how to define treatment-resistant depression and how well newer treatments work over the long term. This guide reports what guidelines and research reviews say and does not give individual medical advice.

Keywords: treatment-resistant depression, augmentation, ketamine, electroconvulsive therapy, transcranial magnetic stimulation

Get Help Now

Anyone who is thinking about suicide or self-harm, or who feels unable to cope, should contact a crisis line straight away. People in immediate danger should call their local emergency number.

- United States: the 988 Suicide & Crisis Lifeline takes calls and texts at 988 (988lifeline.org). - United Kingdom: Samaritans can be called free on 116 123 (samaritans.org). - Canada: the Suicide Crisis Helpline takes calls and texts at 9-8-8 (988.ca). - Australia: Lifeline can be called on 13 11 14 (lifeline.org.au).

This guide describes what published clinical guidelines and research reviews say about treating depression that has not improved with earlier treatment. It is not a substitute for advice from a doctor or other health professional who knows a person's situation.

How Treatment Is Chosen

Depression that has not improved enough after treatment is often called treatment-resistant depression (Sforzini et al., 2022). An international expert panel defined it for research as less than 25% improvement after two failed treatments, each given for at least four weeks (Sforzini et al., 2022). A separate consensus paper proposed a broader idea, difficult-to-treat depression (McAllister-Williams et al., 2020). This idea looks at barriers linked to the person, the illness and the treatment itself (McAllister-Williams et al., 2020). A review of 196 articles found that hidden bipolar disorder may lie behind some depression that seems resistant to treatment (Correa et al., 2010). Its authors found at least moderate support for this idea and urged clinicians to look for subtle signs of bipolar disorder (Correa et al., 2010).

The National Institute for Health and Care Excellence (NICE) in England advises a discussion when depression has shown no response at all after 4 weeks on an antidepressant at a recognised dose, or after 4 to 6 weeks of a talking therapy or of both combined (National Institute for Health and Care Excellence, 2022). NICE describes the next step as a shared decision between the person and the clinician, and elsewhere it notes that people have a right to decline treatment (National Institute for Health and Care Excellence, 2022). The Canadian Network for Mood and Anxiety Treatments (CANMAT) guideline uses both terms, difficult-to-treat and treatment-resistant depression (Lam et al., 2024). It describes personalized, stepwise care for adults, built on shared decisions and regular symptom tracking with questionnaires such as the PHQ-9 (Lam et al., 2024). CANMAT presents its advice as guidance for clinicians rather than fixed standards (Lam et al., 2024).

Adding or Switching Medicines

NICE lists several further steps for adults, such as switching to another medicine or therapy, or adding exercise or a talking therapy (National Institute for Health and Care Excellence, 2022). For adding lithium or an antipsychotic, it advises considering referral to, or advice from, a specialist (National Institute for Health and Care Excellence, 2022). NICE also warns that higher doses may not work better and that combining medicines may raise the side-effect burden (National Institute for Health and Care Excellence, 2022). It adds that some antidepressant combinations are dangerous (National Institute for Health and Care Excellence, 2022).

In the trials CANMAT reviewed, adding a second treatment did better than switching, though CANMAT suggests switching first when the first antidepressant brought no response or troublesome side effects (Lam et al., 2024). Switching to a new antidepressant was not better than staying on the same one (Lam et al., 2024).

A network meta-analysis compares many treatments at once. One such review pooled 65 trials with 12,415 adults who had treatment-resistant depression (Nuñez et al., 2022). Of 19 add-on medicines, 10 led to more people responding than placebo, a dummy treatment (Nuñez et al., 2022). Approved antipsychotics, thyroid hormones, the dopamine-acting medicines modafinil and lisdexamfetamine, and lithium appeared to do best (Nuñez et al., 2022).

An older meta-analysis from 1999 found that adding lithium raised the odds of response compared with placebo (Bauer & Döpfmer, 1999). Its core estimate rested on 3 studies with 110 patients that met the authors' dose and duration standards, and adding 6 more studies gave even higher estimates (Bauer & Döpfmer, 1999). The authors concluded that, on efficacy, adding lithium was the first-choice option after an antidepressant alone fails (Bauer & Döpfmer, 1999).

A 2013 meta-analysis pooled 14 short trials, lasting 4 to 12 weeks, of adding an antipsychotic (Spielmans et al., 2013). These medicines modestly lowered depression ratings and raised remission rates compared with placebo (Spielmans et al., 2013). Remission means symptoms have largely cleared. The benefits were small to moderate, with little gain in quality of life (Spielmans et al., 2013). The authors warned that trial design may have inflated the benefits and that side effects may have been under-reported (Spielmans et al., 2013).

Ketamine and Esketamine

Ketamine is a medicine that blocks a brain receptor called the NMDA receptor (Swainson et al., 2021). In the trials one review compared, ketamine was given into a vein and esketamine through the nose (Bahji et al., 2021). An expert review describes both as working quickly in treatment-resistant depression, while safety questions remain (McIntyre et al., 2021).

That comparison review covered 24 trials with 1,877 adults with depression (Bahji et al., 2021). Ketamine through a vein led to higher response and remission rates than esketamine through the nose (Bahji et al., 2021). The two did not differ on overall change in depression scores or on suicidal thinking (Bahji et al., 2021). The studies varied widely, and correcting for publication bias made the effects on response, remission and depression scores smaller (Bahji et al., 2021).

The McIntyre review reports that in March 2019 the United States Food and Drug Administration (FDA) approved esketamine nasal spray, started together with a standard antidepressant, for adults with treatment-resistant depression (McIntyre et al., 2021). A pooled analysis of 167 patients in 10 studies looked at suicidal thoughts (Wilkinson et al., 2018). One dose of ketamine reduced these thoughts within 1 day, and the effect lasted up to 1 week (Wilkinson et al., 2018). Part of this effect seemed separate from changes in mood (Wilkinson et al., 2018). Whether ketamine lowers suicide risk itself is unproven (Wilkinson et al., 2018). In three esketamine trials in adults at imminent risk for suicide that McIntyre and colleagues reviewed, suicidal thinking did not fall significantly more than with placebo, although depression ratings improved quickly (McIntyre et al., 2021).

A 2017 consensus statement addressed off-label ketamine use, meaning use outside its licensed purpose (Sanacora et al., 2017). It said ketamine may help some people, but its limits and risks deserve careful weighing (Sanacora et al., 2017). Reported side effects include dissociation, a sense of feeling detached, and raised blood pressure (Swainson et al., 2021). There is also a risk of misuse (Swainson et al., 2021). For ketamine given into a vein, evidence on long-term safety is insufficient, and whether long-term use damages brain cells is unknown (McIntyre et al., 2021).

The CANMAT guideline lists ketamine and esketamine as second-line options and notes that they are a burden to deliver (Lam et al., 2024). An earlier CANMAT task force named a single dose of ketamine into a vein as a third-line option (Swainson et al., 2021). It found weaker evidence for repeated doses and other routes (Swainson et al., 2021).

Brain Stimulation

Electroconvulsive therapy (ECT) relies on a seizure, which a review describes as required for it to work (Espinoza & Kellner, 2022). That review calls ECT effective, especially for treatment-resistant depression, though how it works is unknown (Espinoza & Kellner, 2022). Its effects on memory are marked but usually short-lived, and stigma limits its use (Espinoza & Kellner, 2022). A meta-analysis of 84 studies with 2,981 patients found thinking problems mainly in the first 3 days after ECT (Semkovska & McLoughlin, 2010). From 4 to 15 days, scores were close to pre-treatment levels, and after 15 days some were better (Semkovska & McLoughlin, 2010). There were no standard tests for memories from before treatment, so that question is less clear (Semkovska & McLoughlin, 2010). CANMAT notes that, except in emergencies, rTMS is generally considered before ECT because it is less invasive (Lam et al., 2024).

Repetitive transcranial magnetic stimulation (rTMS) is another form of brain stimulation (National Institute of Mental Health, 2024). A 2014 review of 18 trials studied adults who had not improved after 2 or more antidepressants (Gaynes et al., 2014). Compared with sham, a fake version, rTMS lowered symptoms and led to more response and remission (Gaynes et al., 2014). In raw numbers, 29% responded with rTMS and 8% with sham (Gaynes et al., 2014). The authors called rTMS a reasonable option after 2 failed medicines, but how long the benefit lasts was unclear (Gaynes et al., 2014). A 2017 network review of 4,233 patients with major depression found that most types of rTMS beat sham (Brunoni et al., 2017). Accelerated, synchronized and deep rTMS did not differ from sham, and the results overall were imprecise (Brunoni et al., 2017).

The United States National Institute of Mental Health (NIMH) lists ECT and rTMS among brain stimulation therapies (National Institute of Mental Health, 2024). NIMH notes that these are used less often than therapy or medicine, and that some types are still experimental (National Institute of Mental Health, 2024). The National Health Service (NHS) in the United Kingdom says a specialist sometimes recommends brain stimulation for severe depression that has not responded to other treatment (National Health Service, 2023).

What Is Still Uncertain

Studies have not defined treatment-resistant depression in the same way, which makes results harder to compare (Nuñez et al., 2022). An international panel offered shared definitions for trials to address this (Sforzini et al., 2022). Yet some of its agreement was only moderate and awaits confirmation, and its polling method is hard to standardize (Sforzini et al., 2022). The group that proposed the difficult-to-treat idea saw it as clinically useful (McAllister-Williams et al., 2020). However, it rests largely on expert opinion and may be too broad for the trials regulators review (McAllister-Williams et al., 2020).

Pooled trials show that several add-on medicines beat placebo (Nuñez et al., 2022). Yet trial length varied, few trials compared the same pair of treatments, and older studies had weaker designs (Nuñez et al., 2022). More head-to-head trials of add-on medicines are still needed (Nuñez et al., 2022). For ketamine, the review notes that side effects such as dissociation may let people guess which treatment they received, and that this and expectations could make the benefit look larger (McIntyre et al., 2021). No rigorous head-to-head trial has compared ketamine given into a vein with esketamine nasal spray, and long-term safety evidence is lacking for ketamine given into a vein, while esketamine has safety data for up to 1 year (McIntyre et al., 2021). CANMAT adds that early studies of a new treatment tend to report larger effects than later studies (Lam et al., 2024).

Learn More

More detail is in the full article on treatment-resistant depression and the guide to depression treatment. There is also a guide to signs that treatment is not working.

Frequently Asked Questions

What does treatment-resistant depression mean?

For research, an expert panel defined it as less than 25% improvement after two failed treatments, each given for at least four weeks (Sforzini et al., 2022).

What do doctors check before changing treatment?

A review found that hidden bipolar disorder may explain some depression that seems resistant, and its authors supported screening for it (Correa et al., 2010).

Is adding a medicine better than switching?

In the trials the Canadian CANMAT guideline reviewed, adding a second treatment did better than switching (Lam et al., 2024). Switching antidepressants was not better than staying on the same one (Lam et al., 2024).

How quickly can ketamine affect suicidal thoughts?

A pooled analysis found that one dose reduced suicidal thoughts within 1 day, lasting up to 1 week (Wilkinson et al., 2018). Whether it lowers suicide risk itself is unproven (Wilkinson et al., 2018).

Does ECT harm memory?

A meta-analysis found thinking problems mainly in the first 3 days after ECT, with scores back near earlier levels within about two weeks (Semkovska & McLoughlin, 2010).

Who decides which treatment comes next?

NICE in England describes the next step as a shared decision between the person and the clinician (National Institute for Health and Care Excellence, 2022).

How This Article Was Prepared

This is a plain-language patient guide, not a systematic review. Following medical sourcing guidance, it rests on secondary sources rather than single studies: five clinical guidelines, 12 reviews of the research and two pages from public health agencies.

- Included: 19 sources, each confirmed against the publisher's or indexer's own record. 11 read in full text and eight from their abstracts. Agency and guideline pages were read on the publisher's own site. Abstracts came from PubMed, Crossref and OpenAlex. - Identifiers: 16 references carry a PubMed ID and eight a PubMed Central ID, each confirmed by the National Library of Medicine against the cited DOI. - Retractions: 16 sources were checked for retractions and editorial notices; none was retracted. - Publication dates: one from the 1990s, seven from the 2010s and 11 from 2020 or later. - Checked against sources: each of the 84 cited sentences was matched to a passage in its source, and an independent reviewer checked the article against those sources over four passes before publication. - Limits: a short guide summarises selected sources and cannot cover every symptom or situation; it is not a diagnosis or a substitute for seeing a health professional. Each sentence was accepted only after its cited source had been searched for contrary evidence.

See our Editorial Policy for the full method.

References

Bahji, A., Vazquez, G. H., & Zarate, C. A., Jr. (2021). Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of Affective Disorders, 278, 542-555. https://doi.org/10.1016/j.jad.2020.09.071 PMID: 33022440 · PMCID: PMC7704936

Bauer, M., & Döpfmer, S. (1999). Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. Journal of Clinical Psychopharmacology, 19(5), 427-434. https://doi.org/10.1097/00004714-199910000-00006 PMID: 10505584

Brunoni, A. R., Chaimani, A., Moffa, A. H., Razza, L. B., Gattaz, W. F., Daskalakis, Z. J., & Carvalho, A. F. (2017). Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: A systematic review with network meta-analysis. JAMA Psychiatry, 74(2), 143-152. https://doi.org/10.1001/jamapsychiatry.2016.3644 PMID: 28030740

Correa, R., Akiskal, H., Gilmer, W., Nierenberg, A. A., Trivedi, M., & Zisook, S. (2010). Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? Journal of Affective Disorders, 127(1-3), 10-18. https://doi.org/10.1016/j.jad.2010.06.036 PMID: 20655113

Espinoza, R. T., & Kellner, C. H. (2022). Electroconvulsive therapy. New England Journal of Medicine, 386(7), 667-672. https://doi.org/10.1056/NEJMra2034954 PMID: 35172057

Gaynes, B. N., Lloyd, S. W., Lux, L., Gartlehner, G., Hansen, R. A., Brode, S., Jonas, D. E., Swinson Evans, T., Viswanathan, M., & Lohr, K. N. (2014). Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 75(5), 477-489. https://doi.org/10.4088/jcp.13r08815 PMID: 24922485

Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., Blier, P., Blumberger, D. M., Brietzke, E., Chakrabarty, T., Do, A., Frey, B. N., Giacobbe, P., Gratzer, D., Grigoriadis, S., Habert, J., Husain, M. I., Ismail, Z., McGirr, A., . . . Milev, R. V. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. The Canadian Journal of Psychiatry, 69(9), 641-687. https://doi.org/10.1177/07067437241245384 PMID: 38711351 · PMCID: PMC11351064

McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., Soares, J. C., Vieta, E., Young, A. H., Papadopoulos, A., & Rush, A. J. (2020). The identification, assessment and management of difficult-to-treat depression: An international consensus statement. Journal of Affective Disorders, 267, 264-282. https://doi.org/10.1016/j.jad.2020.02.023 PMID: 32217227

McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D. V., Lopez Jaramillo, C., Kasper, S., Kratiuk, K., Lee, J. G., Lee, Y., Lui, L. M. W., Mansur, R. B., Papakostas, G. I., Subramaniapillai, M., Thase, M., Vieta, E., Young, A. H., Zarate, C. A., Jr., & Stahl, S. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry, 178(5), 383-399. https://doi.org/10.1176/appi.ajp.2020.20081251 PMID: 33726522 · PMCID: PMC9635017

National Health Service. (2023, July 5). Treatment - Depression in adults. NHS. https://www.nhs.uk/mental-health/conditions/depression-in-adults/treatment/

National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NICE guideline NG222). https://www.nice.org.uk/guidance/ng222/chapter/Recommendations

National Institute of Mental Health. (2024). Depression (NIH Publication No. 24-MH-8079). U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/publications/depression

Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Gardea Resendez, M., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., Wang, Z., & Singh, B. (2022). Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. Journal of Affective Disorders, 302, 385-400. https://doi.org/10.1016/j.jad.2021.12.134 PMID: 34986373 · PMCID: PMC9328668

Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., & Nemeroff, C. B. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399-405. https://doi.org/10.1001/jamapsychiatry.2017.0080 PMID: 28249076

Semkovska, M., & McLoughlin, D. M. (2010). Objective cognitive performance associated with electroconvulsive therapy for depression: A systematic review and meta-analysis. Biological Psychiatry, 68(6), 568-577. https://doi.org/10.1016/j.biopsych.2010.06.009 PMID: 20673880

Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., et al. (2022). A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 27(3), 1286-1299. https://doi.org/10.1038/s41380-021-01381-x PMID: 34907394 · PMCID: PMC9095475

Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013). Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Medicine, 10(3), e1001403. https://doi.org/10.1371/journal.pmed.1001403 PMID: 23554581 · PMCID: PMC3595214

Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., McIntyre, R. S., Milev, R. V., Parikh, S. V., Schaffer, A., Taylor, V. H., Tourjman, V., van Ameringen, M., Yatham, L. N., Ravindran, A. V., & Lam, R. W. (2021). The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the use of racemic ketamine in adults with major depressive disorder. The Canadian Journal of Psychiatry, 66(2), 113-125. https://doi.org/10.1177/0706743720970860 PMID: 33174760 · PMCID: PMC7918868

Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., Jr., & Sanacora, G. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. American Journal of Psychiatry, 175(2), 150-158. https://doi.org/10.1176/appi.ajp.2017.17040472 PMID: 28969441 · PMCID: PMC5794524